© 2006 Powles et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution Licens
This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate, with place...
One in four breast cancer patients is at risk of developing bone metastases in her life time. The ea...
The fracture impact of adjuvant bisphosphonates in breast cancer is not defined with most trials rep...
Introduction Experimental and clinical data show that the oral bisphosphonate clodronate (Bonefos®)...
INTRODUCTION: Experimental and clinical data show that the oral bisphosphonate clodronate (Bonefo...
Purpose: To assess whether clodronate can reduce frequency of skeletal morbidity in women with lytic...
Authors ’ disclosures of potential con-flicts of interest and author contribu-tions are found at the...
Bisphosphonates have been studied in randomised trials in early breast cancer to investigate their a...
Michael GnantDepartment of Surgery, Medical University of Vienna, Vienna, AustriaAbstract: Most wome...
Bisphosphonates have been studied in randomised trials in early breast cancer to investigate their a...
Bone is the most common site of metastasis from breast cancer. Bone metastases from breast cancer ar...
Bisphosphonates have been studied in randomised trials in early breast cancer to investigate their a...
Purpose: To update recommendations of the American Society of Clinical Oncology (ASCO)-Ontario Heal...
PURPOSE: To update recommendations of the American Society of Clinical Oncology (ASCO)-Ontario Healt...
Metastasis to bone, and indeed potentially to other sites, results from the numerous interactions be...
This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate, with place...
One in four breast cancer patients is at risk of developing bone metastases in her life time. The ea...
The fracture impact of adjuvant bisphosphonates in breast cancer is not defined with most trials rep...
Introduction Experimental and clinical data show that the oral bisphosphonate clodronate (Bonefos®)...
INTRODUCTION: Experimental and clinical data show that the oral bisphosphonate clodronate (Bonefo...
Purpose: To assess whether clodronate can reduce frequency of skeletal morbidity in women with lytic...
Authors ’ disclosures of potential con-flicts of interest and author contribu-tions are found at the...
Bisphosphonates have been studied in randomised trials in early breast cancer to investigate their a...
Michael GnantDepartment of Surgery, Medical University of Vienna, Vienna, AustriaAbstract: Most wome...
Bisphosphonates have been studied in randomised trials in early breast cancer to investigate their a...
Bone is the most common site of metastasis from breast cancer. Bone metastases from breast cancer ar...
Bisphosphonates have been studied in randomised trials in early breast cancer to investigate their a...
Purpose: To update recommendations of the American Society of Clinical Oncology (ASCO)-Ontario Heal...
PURPOSE: To update recommendations of the American Society of Clinical Oncology (ASCO)-Ontario Healt...
Metastasis to bone, and indeed potentially to other sites, results from the numerous interactions be...
This phase III study compared the efficacy of the new potent bisphosphonate, ibandronate, with place...
One in four breast cancer patients is at risk of developing bone metastases in her life time. The ea...
The fracture impact of adjuvant bisphosphonates in breast cancer is not defined with most trials rep...